Drug
Darinaparsin clinical trials
Also written ZIO-101.
- studies test it
- 14
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 4 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Alaunos Therapeutics (10) · Solasia Pharma K.K. (3) · M.D. Anderson Cancer Center (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (1) · Doxorubicin (1) · Vincristine (1) · Prednisone (1)
Studies
Open first, then newest update. How each study uses darinaparsin is read from its arms, and is right about nine times in ten.
Testing it · 14
- Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow CancersTerminatedPhase 2Alaunos TherapeuticsNCT00421213Written as Darinaparsin
- A Phase-II Trial of ZIO 101 in Advanced Hepatocellular CarcinomaTerminatedPhase 2Alaunos TherapeuticsNCT00423306Written as Darinaparsin
- A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001bCompletedPhase 2Alaunos TherapeuticsNCT00423644Written as Darinaparson
- Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and LymphomasCompletedPhase 1Alaunos TherapeuticsNCT00592163Written as ZIO-101-C (Darinaparsin)
- Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's LymphomasCompletedPhase 1Alaunos TherapeuticsNCT00591422Written as ZIO-101-C (Darinaparsin)
- A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedPhase 2Solasia Pharma K.K.NCT02653976Written as SP-02L (darinaparsin for injection)
- A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)CompletedPhase 1Solasia Pharma K.K.NCT01435863Written as SP-02L (darinaparsin for injection)
- A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in KoreaCompletedPhase 1Solasia Pharma K.K.NCT01689220Written as SP-02L (darinaparsin for injection)
- Phase I Trial of ZIO-101 in Patients With Solid TumorsCompletedPhase 1M.D. Anderson Cancer CenterNCT00509782Written as ZIO-101
- Study of Oral Darinaparsin in Patients With Advanced Solid TumorsCompletedPhase 1Alaunos TherapeuticsNCT01139346Written as darinaparsin
- A Phase I Trial of ZIO-101 in Solid TumorsCompletedPhase 1Alaunos TherapeuticsNCT00591396Written as ZIO-101 (Darinaparsin)
- A Phase I Trial of ZIO-101 in Hematologic CancersCompletedPhase 1Alaunos TherapeuticsNCT00592046Written as ZIO-101 (Darinaparsin)
- Study of ZIO-101 in Multiple MyelomaCompletedPhase 1/2Alaunos TherapeuticsNCT00303199Written as ZIO-101 (Darinaparsin)
- Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat LymphomaWithdrawnPhase 1Alaunos TherapeuticsNCT01139359Written as darinaparsin
Codes
What other systems call darinaparsin · ClinicalTrials.gg INT004995
- MeSH (NLM) C515055darinaparsinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 9XX54M675GDARINAPARSINConfirmed FDA, NLM, Wikidata
- Wikidata Q27166111darinaparsinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61490DarinaparsinOne source FDA
- DrugBank DB06179One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C515055 | darinaparsin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 9XX54M675G | DARINAPARSIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27166111 | darinaparsin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61490 | Darinaparsin | One source FDA |
| DrugBank | DB06179 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.